Cencora (COR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Cencora

NYSE•Healthcare•Medical Distribution

$309.41-9.09(-0.03%)After hours

Market Cap

$60.22B

P/E

22.9x

P/S

0.2x

P/B

19.7x

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

How this company scores

AverageMetricSide Score: 58/100

Strongest: Growth (21/25); weakest: Balance Sheet & Red Flags (6/25).

Profitability11/25

Growth21/25

Balance Sheet & Red Flags6/25

Cash & Earnings Quality20/25

Strengths

Rising free cash flowHigh ROERising earningsConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 22.9x5y range 16.3x – 40.6x

Currently near its 20-quarter median.

P/S · 0.2x5y range 0.1x – 0.2x

Currently near its 20-quarter median.

P/B · 19.7x5y range 17.7x – 192.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Leverage Risk

Red Flag

D/E ratio is 3.8 — heavily leveraged and vulnerable to rising rates or cash flow dips.

Price & Volume

Market Cap $60.22B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $332.77B
Q. Revenue: $84.75B
TTM EBITDA: $4.07B
TTM Op. Income: $3.04B
Q. Op. Income: $1.12B
TTM Net Income: $2.62B
Q. Net Income: $763.52M
EPS: $3.95
Shares Out.: $193.15M

$332.77B in TTM revenue grew 5.1% YoY, reaching $84.75B last quarter. TTM EBITDA of $4.07B and TTM operating income of $3.04B show growth is flowing through to the bottom line. TTM net income of $2.62B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 1.6%
Op. Margin: 1.3%
Net Margin: 0.9%

Op. margin of 1.3% is up 0.2% YoY — cost efficiency is improving. Net margin at 0.9% Over the past year, operating margin is up 23% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 22.9x
P/S Ratio: 0.2x
P/B Ratio: 19.7x

At 22.9x P/E, the stock trades within typical market levels. P/S of 0.2x and P/B of 19.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $83.81B
Cash: $2.82B
Long-Term Debt: $11.44B
Book Value: $3.05B
D/E Ratio: 3.8
Debt/EBITDA: 8.2

With $83.81B in assets and $11.44B in long-term debt, D/E is 3.8and book value is $3.05B — elevated leverage, meaning significant financial risk in a downturn. Over the past year, debt/equity is down 8% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $2.65B
TTM Free Cash Flow: $4.06B
FCF Margin: 1.2%
FCF / Net Income: 1.5

TTM FCF of $4.06B on $2.65B in operating cash flow. The FCF / Net Income ratio of 1.5x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 256% — an improving trend.